InChI: | InChI=1/C16H23N3O4.CH4O3S/c1-2-22-15(21)12-7-9-13(10-8-12)23-14(20)6-4-3-5-11-19-16(17)18;1-5(2,3)4/h7-10H,2-6,11H2,1H3,(H4,17,18,19);1H3,(H,2,3,4) |
Specification: |
The IUPAC name of Gabexate mesylate is Ethyl 4-[6-(diaminomethylideneamino)hexanoyloxy]benzoate ; Methanesulfonic acid . With the CAS registry number 56974-61-9, it is also can be called as Ethyl p-(6-guanidinohexanoxyloxy)benzoate methanesulfonate ; Ethyl p-(6-guanidinohexanoyloxy) benzoate methanesulfonate ; FOY ; Gabexate mesilate ; Gabexato mesilato ; Gabexato mesilato [Spanish] ; p-Hydroxybenzoic acid ethyl ester 6-guanidinohexanoate mesilate ; Benzoic acid, 4-((6-((aminoiminomethyl)amino)-1-oxohexyl)oxy)-, ethyl ester, monomethanesulfonate . Gabexate mesylate (CAS NO.56974-61-9) is white crystal. It is soluble in alcohol, chloroform or water, slightly soluble in acetone, almost insoluble in ether . It belongs to the product categories: active pharmaceutical ingredients;benzoic acid.
Properties of Gabexate mesylate : (1)Enthalpy of Vaporization: 77.9 kJ/mol ; (2)Vapour Pressure: 1.83E-10 mmHg at 25 °C ; (3)H-Bond Donor: 3 ; (4)H-Bond Acceptor: 10 ; (5)Rotatable Bond Count: 11 ; (6)Tautomer Count: 2 ; (7)Exact Mass: 417.156971 ; (8)MonoIsotopic Mass: 417.156971 ; (9)Topological Polar Surface Area: 171 ; (10)Heavy Atom Count: 28
Gabexate mesylate (CAS NO.56974-61-9) is non-peptide protease inhibitors. It is used for acute pancreatitis, chronic recurrent acute pancreatitis, postoperative acute pancreatitis.
You can still convert the following datas into molecular structure:
(1)Canonical SMILES: CCOC(=O)C1=CC=C(C=C1)OC(=O)CCCCCN=C(N)N.CS(=O)(=O)O;
(2)InChI: InChI=1S/C16H23N3O4.CH4O3S/c1-2-22-15(21)12-7-9-13(10-8-12)23-14(20)6-4-3-5-11-19-16(17)18;1-5(2,3)4/h7-10H,2-6,11H2,1H3,(H4,17,18,19);1H3,(H,2,3,4) ;
(3)InChIKey: DNTNDFLIKUKKOC-UHFFFAOYSA-N
Toxicity data of is as following:
Organism |
Test Type |
Route |
Reported Dose (Normalized Dose) |
Effect |
Source |
dog |
LDLo |
intravenous |
20mg/kg (20mg/kg) |
SENSE ORGANS AND SPECIAL SENSES: MYDRIASIS (PUPILLARY DILATION): EYE
BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)
LUNGS, THORAX, OR RESPIRATION: DYSPNEA |
Nippon Yakurigaku Zasshi. Japanese Journal of Pharmacology. Vol. 71, Pg. 71, 1975. |
mouse |
LD50 |
intravenous |
218mg/kg (218mg/kg) |
BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD
LUNGS, THORAX, OR RESPIRATION: DYSPNEA
KIDNEY, URETER, AND BLADDER: URINE VOLUME INCREASED |
Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 15, Pg. 1203, 1987. |
mouse |
LD50 |
oral |
8gm/kg (8000mg/kg) |
BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)
BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY)
GASTROINTESTINAL: CHANGES IN STRUCTURE OR FUNCTION OF SALIVARY GLANDS |
Oyo Yakuri. Pharmacometrics. Vol. 9, Pg. 743, 1975. |
mouse |
LD50 |
subcutaneous |
4500mg/kg (4500mg/kg) |
SKIN AND APPENDAGES (SKIN): CORROSIVE: AFTER TOPICAL EXPOSURE |
Oyo Yakuri. Pharmacometrics. Vol. 9, Pg. 743, 1975. |
rabbit |
LDLo |
intravenous |
50mg/kg (50mg/kg) |
BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)
LUNGS, THORAX, OR RESPIRATION: DYSPNEA |
Nippon Yakurigaku Zasshi. Japanese Journal of Pharmacology. Vol. 71, Pg. 71, 1975. |
rat |
LD50 |
intravenous |
79mg/kg (79mg/kg) |
|
Oyo Yakuri. Pharmacometrics. Vol. 9, Pg. 743, 1975. |
rat |
LD50 |
oral |
6480mg/kg (6480mg/kg) |
BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)
BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY)
GASTROINTESTINAL: CHANGES IN STRUCTURE OR FUNCTION OF SALIVARY GLANDS |
Oyo Yakuri. Pharmacometrics. Vol. 9, Pg. 743, 1975. |
rat |
LD50 |
subcutaneous |
4020mg/kg (4020mg/kg) |
|
Oyo Yakuri. Pharmacometrics. Vol. 9, Pg. 743, 1975. |
|